文献速递乳腺癌放疗

腋窝侧胸血管交汇处不是乳腺癌相关淋巴水肿的风险器官

The Axillary Lateral Vessel Thoracic Junction Is Not an Organ at Risk for Breast Cancer-Related Lymphedema.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-04-13

研究纳入2013至2018年接受辅助区域淋巴结照射的II-III期乳腺癌患者378例,回顾性勾画腋窝侧胸血管交汇处(ALTJ)并分析剂量与乳腺癌相关淋巴水肿(BCRL)的关联。多因素分析显示ALTJ各项剂量指标均与BCRL风险无关,仅年龄、体重指数和淋巴结切除数增加与BCRL风险升高相关。作者结论认为ALTJ未被验证为降低BCRL风险的关键风险器官,在发现此类风险器官之前不应为减少BCRL而修改腋窝PTV或降低剂量。

要点

  • 378例接受辅助区域淋巴结照射的II-III期乳腺癌患者中,5年BCRL累积发生率为25.8%。
  • 多因素分析中ALTJ各项剂量指标均与BCRL风险无关。
  • 年龄增加、体重指数增加和淋巴结切除数增加与BCRL风险升高相关。

核心结论

  • ALTJ未被验证为降低BCRL风险的关键风险器官。
  • 在发现此类风险器官之前,不应为减少BCRL而修改腋窝PTV或降低剂量。

研究设计与样本

  • 回顾性识别2013至2018年接受辅助区域淋巴结照射的II-III期乳腺癌患者,排除放疗前已患BCRL者。
  • BCRL定义为任一次就诊时患侧与对侧臂围差>2.5 cm,或≥2次就诊时臂围差≥2 cm。
  • 回顾性勾画ALTJ并收集剂量指标,采用Cox比例风险回归模型检验临床与剂量参数和BCRL发生的关联。
  • 研究人群共378例,中位年龄53岁,中位体重指数28.4 kg/m2,中位腋窝淋巴结切除数18枚,71%接受乳房切除术。
  • 中位随访70个月(四分位距55-89.7个月)。

主要发现

  • 101例发生BCRL,中位发生时间18.9个月(四分位距9.9-32.4个月),5年BCRL累积发生率为25.8%。
  • 多因素分析中ALTJ各项指标均与BCRL风险无关。
  • 仅年龄增加、体重指数增加和淋巴结切除数增加与BCRL风险升高相关。
  • 6年局部区域复发率为3.2%,腋窝复发率为1.7%,孤立腋窝复发率为0%。

临床怎么用

  • 作者结论认为ALTJ未被验证为降低BCRL风险的关键风险器官,在发现此类风险器官之前不应为减少BCRL而修改腋窝PTV或降低剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer-related lymphedema (BCRL) is a treatment complication that significantly reduces patient quality of life. Regional nodal irradiation (RNI) may increase the risk of BCRL. Recently, a region of the axilla known as the axillary-lateral thoracic vessel juncture (ALTJ) was identified as a potential organ at risk (OAR). Here, we set out to validate whether radiation dose to the ALTJ is associated with BCRL. METHODS AND MATERIALS: We identified patients with stage II-III breast cancer treated with adjuvant RNI from 2013 to 2018, excluding those with BCRL preradiation. We defined BCRL as difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any 1 encounter or ≥2 cm on ≥2 visits. All patients suspected of having BCRL at routine follow-up visits were referred to physical therapy for confirmation. The ALTJ was retrospectively contoured and dose metrics were collected. Cox proportional hazards regression models were used to test the association between clinical and dosimetric parameters with the development of BCRL. RESULTS: The study population included 378 patients with a median age of 53 years, median body mass index of 28.4 kg/m2, and median of 18 axillary nodes removed; 71% underwent mastectomy. Median follow-up was 70 months (interquartile range, 55-89.7 months). BCRL developed in 101 patients at a median of 18.9 months (interquartile range, 9.9-32.4 months), with a corresponding 5-year cumulative incidence BCRL of 25.8%. On multivariate analysis, none of the ALTJ metrics were associated with BCRL risk. Only increasing age, increasing body mass index, and increasing number of nodes were associated with a higher risk of developing BCRL. The 6-year locoregional recurrence rate was 3.2%, the axillary recurrence rate was 1.7%, and the isolated axillary recurrence rate was 0%. CONCLUSIONS: The ALTJ is not validated as a critical OAR for reducing BCRL risk. Until such an OAR is discovered, the axillary PTV should not be modified or dose reduced in efforts to reduce BCRL.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Healy E, Beyer S, Jhawar S, et al. The Axillary Lateral Vessel Thoracic Junction Is Not an Organ at Risk for Breast Cancer-Related Lymphedema. Int J Radiat Oncol Biol Phys. 2023. PMID: 37059233. doi:10.1016/j.ijrobp.2023.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。